1. Advances in Lymphoma

2. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

3. Ibrutinib Monotherapy

4. GS-9973 and Idelasib in Patients With R/R CLL

5. ABT-199 in Patients With R/R CLL/SLL

6. Hodgkin Lymphoma

7. ABVD With and Without Bleomycin and/or Dacarbazine

8. Brentuximab Vedotin Followed by ABVD in Patients With Untreated NHL

9. Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma

10. Follicular Lymphoma

11. Prognostic Value of PET-CT After FL Therapy in FL

12. FOLL05, 5-Year Follow-up

13. Alliance/CALGB 50803 Lenalidomide Plus Rituximab for Untreated FL

14. ROMULUS Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients With R/R FL

15. Diffuse Large B-Cell Lymphoma

16. Two Different R-CHOP Variants

17. ABT-199 for DLBCL

18. Monitoring MRD Using Cellular and Acellular Blood DNA

19. Mantle Cell Lymphoma

20. R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed Patients With MCL

21. Subcutaneous Bortezomib in Relapsed MCL

22. Safety of Ibrutinib in R/R MCL

23. T-Cell Lymphoma

24. Alisertib for PTCL

25. Response to Romidepsin by Number of Lines of Prior Therapies in R/R PTCL

26. Topical SHP-141 for CTCL

27. Outcomes of Patients With PTCL From the BCCA Registry After Standard Chemotherapy

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)

31. References

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)